Stereotaxis, Inc. STXS
Set alert
At close · Nov 2
After hours · Nov 2, 6:47 PM ET
- YTD
- -61.73%
- 1 year
- -69.76%
- Open
- 0.8758
- Prev close
- 0.8626
- Mkt cap
- 88.19M
- Vol
- 532.67K
- Avg vol
- 591.81K
- EPS
- -0.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8702
- High
- 0.9267
- Forward P/E
- -13.06
- Beta
- 1.55
- Short ratio
- 6.26
- Inst. own
- 48.48%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.14
- 1y target
- 4.50
News
-
18 hours ago benzinga.com
Stereotaxis Announces 100% Clinical Success Rate For Its Robocath's Robotic System At Transcatheter Cardiovascular Therapeutics Conference; Technical Success Reported At 95%
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the findings from the first-in-human clinical results for…
18 hours ago globenewswire.com
First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT
ST. LOUIS and ROUEN, France, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today…
-
3 days ago benzinga.com
Canon Medical Systems, Stereotaxis Announce Technology Compatibility And Commercial Collaboration To Pair Alphenix Interventional Imaging Platform With Genesisx Robotic Magnetic Navigation System
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon boothTUSTIN,…
3 days ago globenewswire.com
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
Collaboration brings together Canon's Alphenix interventional fluoroscopy system and Stereotaxis' GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN,…
-
1 week ago benzinga.com
Stereotaxis Says Pauls Stradiņš Clinical University Hospital In Latvia, Establishes Robotic Center For Treatment Of Cardiac Arrhythmias In Latvia And Treats Initial Patients With Genesis Robotic Magnetic Navigation System
Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst…
1 week ago globenewswire.com
Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls…
1 week ago globenewswire.com
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it…
1 month ago globenewswire.com
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society's HRX 2026
New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept.
2 months ago globenewswire.com
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the…
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3
Citizens analyst Daniel Stauder maintains Stereotaxis (AMEX:STXS) with a Market Outperform and lowers the price target from $4 to $3.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $3
TD Cowen analyst Joshua Jennings maintains Stereotaxis (AMEX:STXS) with a Buy and lowers the price target from $5 to $3.
2 months ago seekingalpha.com
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite…
2 months ago zacks.com
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
-
2 months ago benzinga.com
Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
2 months ago globenewswire.com
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business…
3 months ago globenewswire.com
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it…
3 months ago globenewswire.com
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac…
3 months ago benzinga.com
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
3 months ago globenewswire.com
Stereotaxis Completes Acquisition of Robocath
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today…
5 months ago marketbeat.com
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products…
-
5 months ago benzinga.com
Piper Sandler Reiterates Overweight on Stereotaxis, Lowers Price Target to $3.5
Piper Sandler analyst Adam Maeder reiterates Stereotaxis (AMEX:STXS) with a Overweight and lowers the price target from $4 to $3.5.
5 months ago seekingalpha.com
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
5 months ago benzinga.com
Stereotaxis Q1 2026 Earnings Call Transcript
Stereotaxis Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Stereotaxis Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $6.291M Miss $8.620M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 14.29 percent increase over losses of $(0.07)…
5 months ago globenewswire.com
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
Proprietary robotically-navigated MAGiC catheter received U. S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital…
6 months ago zacks.com
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
6 months ago globenewswire.com
Stereotaxis Announces First MAGiC Procedures in the United States
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first…
6 months ago benzinga.com
Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover
Stereotaxis to acquire Robocath, advancing robotic endovascular tech and accelerating expansion into cardiology and neuro markets.
-
6 months ago benzinga.com
Stereotaxis To Acquire Robocath, A Venture-Backed Producer Of Robotic Technologies For Interventional Cardiology And Neurointerventions; Terms Not Disclosed
This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver…
-
7 months ago benzinga.com
Stereotaxis Receives FDA 510(k) Clearance For Synchrony System
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
STX Semiconductor Co. Files Prospectus To Offer Up To $100M In Debt, Equity, Warrants, Rights, And Units
$100,000,000 Debt SecuritiesCommon StockPreferred StockWarrantsRightsUnitsWe may offer and sell from time to time, in one or more offerings, up to $100,000,000 in the aggregate of debt securities,…
7 months ago benzinga.com
Stereotaxis Q4 Earnings Summary & Key Takeaways
Stereotaxis Q4 Earnings Summary & Key Takeaways
-
7 months ago benzinga.com
Stereotaxis Q4 EPS $(0.06), Inline, Sales $8.642M Miss $9.080M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period…
-
10 months ago benzinga.com
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
-
10 months ago benzinga.com
Citizens Initiates Coverage On Stereotaxis with Market Outperform Rating, Announces Price Target of $4
Citizens analyst Daniel Stauder initiates coverage on Stereotaxis (AMEX:STXS) with a Market Outperform rating and announces Price Target of $4.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
11 months ago benzinga.com
Stereotaxis Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $7.464M Miss $8.375M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.08)…
11 months ago benzinga.com
Earnings Scheduled For November 11, 2025
Earnings Scheduled For November 11, 2025
-
11 months ago benzinga.com
Stereotaxis Granted FDA 510(k) For Its GenesisX RMN System With Navigant Workstation And Cardiodrive As Substantially Equivalent
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251792
-
11 months ago benzinga.com
A Look at Stereotaxis's Upcoming Earnings Report
A Look at Stereotaxis's Upcoming Earnings Report
-
1 year ago benzinga.com
Stereotaxis Receives CE Mark, Seeks FDA Approval for Synchrony Surgical Robotics System
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k)…
1 year ago benzinga.com
New Robotic System Promises Faster, Safer Care For Arrhythmia Patients
Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions.